This Decision Letter sets out the Programme Terms of a Programme.

1. **Country:** Sri Lanka

2. **Grant Number:** 1518-LKA-25c-X / 1518-LKA-25b-X / 15-LKA-08h-Y

3. **Date of Decision Letter:** 22 December 2014

4. **Date of the Partnership Framework Agreement:** 03 April 2014

5. **Programme Title:** NVS, IPV Routine

6. **Vaccine type:** Inactivated Polio Vaccine (IPV)

7. **Requested product presentation and formulation of vaccine:** Inactivated Polio Vaccine, 5 dose(s) per vial, LIQUID

8. **Programme Duration:** 2015 - 2018

9. **Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):**

   Please note that endorsed or approved amounts for 2017 and 2018 will be communicated in due course, taking into account updated information on country requirements and following GAVI's review and approval processes.

<table>
<thead>
<tr>
<th>Programme Budget (US$)</th>
<th>2015</th>
<th>2016</th>
<th>Total⁴</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>US$1,341,090</td>
<td>US$1,042,500</td>
<td>2,383,590</td>
</tr>
</tbody>
</table>

10. **Vaccine Introduction Grant:** US$297,000 sent to Sri Lanka on 25 July 2014 as per decision letter dated 30 June 2014

---

¹ This Decision Letter replaces and supplants the Decision Letter dated 30 June 2014 issued to the Country with a 10-dose product presentation. Since that time, WHO has pre-qualified a 5-dose product presentation. As implementation has not started, Gavi is providing the government with the 5-dose product presentation as set out in this Decision Letter.

² Please refer to section 18 for additional information on IPV presentation.

³ This is the entire duration of the programme.

⁴ This is the total amount endorsed by GAVI for 2014 to 2016.
11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement): The Annual Amount for 2015 has changed from the previous Decision Letter which was issued on 30 June 2014 and which has now been replaced by this Decision Letter:

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with GAVI funds in each year</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of IPV vaccines doses</td>
<td>651,300</td>
</tr>
<tr>
<td>Number of AD syringes</td>
<td>601,200</td>
</tr>
<tr>
<td>Number of re-constitution syringes</td>
<td></td>
</tr>
<tr>
<td>Number of safety boxes</td>
<td>6,625</td>
</tr>
<tr>
<td>Annual Amounts (US$)</td>
<td>US$1,341,090</td>
</tr>
</tbody>
</table>

12. Procurement agency: UNICEF

13. Self-procurement: Not applicable

14. Co-financing obligations: N/A
   GAVI’s usual co-financing requirements do not apply to IPV. However, Sri Lanka is encouraged to contribute to vaccine and/or supply costs for IPV.

15. Operational support for campaigns: N/A

16. The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts:

<table>
<thead>
<tr>
<th>Reports, documents and other deliverables</th>
<th>Due dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annual Progress Report or equivalent</td>
<td>15 May 2015</td>
</tr>
</tbody>
</table>

17. Financial Clarifications: The Country shall provide the following clarifications to GAVI*: Not applicable
   *Failure to provide the financial clarifications requested may result in GAVI withholding further disbursements

18. Other conditions: Not applicable.

Signed by, On behalf of the GAVI Alliance
Hind Khatib-Othman
Managing Director, Country Programmes
22 December 2014

---

5 This is the amount that GAVI has approved.